Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
DORZOLAMIDE
Generics (UK) Limited
S01EC03
DORZOLAMIDE
20 Mg/Ml
Eye Drops Solution
Product subject to prescription which may be renewed (B)
Carbonic anhydrase inhibitors
Authorised
2010-09-10
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT DORZOLAMIDE MYLAN 20 MG/ML EYE DROPS, SOLUTION Dorzolamide READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illnessare the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4 WHAT IS IN THIS LEAFLET: 1. What Dorzolamide Mylan is and what it is used for 2. What you need to know before you use Dorzolamide Mylan 3. How to use Dorzolamide Mylan 4. Possible side effects 5. How to store Dorzolamide Mylan 6. Contents of the pack and other information 1. WHAT DORZOLAMIDE MYLAN IS AND WHAT IT IS USED FOR Dorzolamide Mylan is supplied as a sterile eye drop solution. Dorzolamide Mylan contains dorzolamide, a sulfonamide-related compound, as the active ingredient. Dorzolamide belongs to a group of medicines called ophthalmic carbonic anhydrase inhibitors which reduces high pressure in the eye. Dorzolamide is used to lower raised pressure in the eye and to treat glaucoma (open-angle glaucoma, pseudo-exfoliative glaucoma). Dorzolamide Mylan can be used alone or in addition to other medicines which lower the pressure in the eye (so-called beta-blockers). 2. WHAT YOU NEED TO KNOW BEFORE YOU USE DORZOLAMIDE MYLAN DO NOT USE DORZOLAMIDE MYLAN - if you are allergic to dorzolamide Read the complete document
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Dorzolamide Mylan 20 mg/ml Eye Drops Solution 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains 20 mg dorzolamide (as dorzolamide hydrochloride). Excipient with known effect: Each ml of solution contains 0.075 mg benzalkonium chloride. For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Eye drops, solution. Isotonic, buffered, slightly viscous, clear, colourless aqueous solution. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Dorzolamide Mylan 20 mg/ml eye drops solution is indicated: as adjunctive therapy to beta-blockers, as monotherapy in patients unresponsive to beta-blockers or in whom beta-blockers are contraindicated in the treatment of elevated intra-ocular pressure in: ocular hypertension, open-angle glaucoma, pseudo-exfoliative glaucoma. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION POSOLOGY When used as monotherapy, the dose is one drop of dorzolamide in the conjunctival sac of the affected eye(s), three times daily. When used as adjunctive therapy with an ophthalmic beta-blocker, the dose is one drop of dorzolamide in the conjunctival sac of the affected eye(s), two times daily. When another ophthalmic anti-glaucoma agent is substituted by dorzolamide, the agent must be discontinued after proper dosing on one day, and dorzolamide must be started on the next day. If more than one topical ophthalmic medicinal product is being used, the products should be administered at least ten minutes apart. Patients should be instructed to avoid allowing the tip of the dispensing container to contact the eye or surrounding structures. HEALTH PRODUCTS REGULATORY AUTHORITY ________________________________________________________________________________________________________________________ _Date Printed 12/09/2016_ _ Read the complete document